

**DATA SHEET**

**Product Name:** Bexarotene

**Catalog #:** N-3032

**Alt:** CAS# 153559-49-0; 4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic acid; LGD1069, SR-11247

**Source:** Synthetic

**Molecular Mass:** 348.5 C<sub>24</sub>H<sub>28</sub>O<sub>2</sub>

**Analysis:** 98% (TLC); NMR (Conforms)

**Supplied As:** White powder; MP=222-223°C

**Resuspension:** May be dissolved in DMSO (60 mg/ml); or ethanol (10 mg/ml, warm)

**Storage:** Store desiccated as supplied at -20°C for up to 1 year. Store solutions at -20°C for up to 1 week.

**Description:** A highly potent and selective retinoid X receptor (RXR) agonist (EC<sub>50</sub>=28, 25, 20 nM for RXR $\alpha$ ,  $\beta$ ,  $\gamma$  respectively)<sup>1</sup>. Clinically useful antineoplastic agent for cutaneous T-cell lymphoma<sup>2</sup>. Causes complete regression of mammary carcinoma<sup>3</sup>. Bexarotene significantly increases clearance of soluble  $\beta$ -amyloid in a mouse Alzheimer's model and increases cognitive ability<sup>4</sup>. Reverses apoE4-driven brain pathology and behavioral deficits in vivo<sup>5</sup>.

**References:**

1. Boehm, M.F., et al., (1995) J. Med. Chem., 38: 3146
2. Gniadecki, R., et al., (2007) Br. J. Dermatol., 157: 433
3. Bischoff, E.D., et al., (1998) Cancer Res., 58: 479
4. Cramer, P.E., et al., (2012) Science, 335: 1503
5. Boehm-Cagan, A., and Michaelson, D.M., (2014) J. Neurosci., 34: 7293

***For research use only. Not for use in humans.***